A 6-month erenumab treatment significantly reduces consumption of acute migraine-specific and non-specific drugs in patients suffering from EM or CM. Overall, treatment mitigates conversion from EM to CM and medication overuse. Read more: https://t.co/NYl
2,926 followers
778 followers
What can a VR roller coaster ride tell us about migraine? Molly O'Brien will fill you in on the latest migraine news in this week’s Migraine Minute. More info: https://t.co/74RBzKJbJr https://t.co/L4JkZ1yepw https://t.co/8UjpetBl7K https://t.co/WJslRuLt4
6,797 followers
What can a VR roller coaster ride tell us about migraine? Molly O'Brien will fill you in on the latest migraine news in this week’s Migraine Minute. More info: https://t.co/gDqozXyLoO https://t.co/EEVLPdvDH5 https://t.co/deMmtvpbOH https://t.co/mpj1diKebA
232 followers
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials https://t.co/jTaTg8mate